1Friedman LM, Furgberg CD, DeMets DL. Fundamentals of clinical trials [M]. 2nd ed. St. Louis: Mosby, 1995:5-24. 被引量：1
2Fleming TR, Demets DL. Surrogate end points in clinical trials:Are we been misled? [J]. Ann Intern Med, 1996,125:605-613. 被引量：1
3Fleming TR. Surrogate markers in AIDS and cancer trials [J].Stat Med, 1994,13:1423-1432. 被引量：1
4Temple RJ. A regular authority's opinion about surrogate endpoints [M]// Nimmo WS, Tucker GT, eds. Clinical measurement in Drug Evaluation. New York:John Wiley & Sons Ltd, 1995:3-22. 被引量：1
5Prentice RL. Surrogate endpoints in clinical trials:cardiovascular-diseases [J]. Star Med, 1989,8:431-440. 被引量：1
6Pasty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents [J]. JAMA, 1997,277 : 739-745. 被引量：1
7Five-year findings of the hypertension detection and follow-up program.Ⅰ. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group [J]. JAMA, 1979,242 : 2652 -2671. 被引量：1
8Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program(SHEP), SHEP Cooperative Research Group [J]. JAMA, 1991,265 : 2355-2364. 被引量：1
9Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1988 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure [J]. Arch Intern Med, 1988,148:1023-1038. 被引量：1
10Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.(JNC V) [J]. Arch Intern Med, 1993,153:154-183. 被引量：1
5Bucher HC,Guyatt GH,Cook DJ,Holbrook A,McAlister FA.Users'guides to the medical literatrue:XIX.Applying clinical trial results.A.How to use an article measuring the effect of an intervention on surrogate end points[J].JAMA,2000; 19:192 -7 被引量：1
6Stuart G.Baker.Surrogate Endpoints:Wishful Thinking or Reality[J]? J Nall Cancer Inst,2006;98:502-3 被引量：1
8Tseng LN,Sheu WH,Ho ES,Lan HH,Hu CC,Kao CH.Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women[J].Metab Clin Exp,2006;55:741-7 被引量：1
9Collins R,Peto R,MacMahon S,Hebert P,Fiebach NH,Eberlein KA,et al.Blood pressure,stroke,and coronary heart disease.Part 2,Short-term reductions in blood pressure:overview of randomized drug trials in their epidemiological context[J].Lancet,1990;335:827-38 被引量：1
10SHEP Cooperative Research Group.Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension:final results of the systolic hypertension in the elderly program (SHEP)[J].JAMA,1991; 265:3255-64 被引量：1
